Search
AGG-523
go.drugbank.com/drugs/DB15460InvestigationalAGG-523 is under investigation in clinical trial NCT00380900 (Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy subjects and in subjects
Renvistobart
go.drugbank.com/drugs/DB19065InvestigationalRenvistobart is under investigation in clinical trial NCT02913313 (A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors).
AB192
go.drugbank.com/drugs/DB06111ExperimentalAB192 is a DPP IV enzymatic activity inhibitor.
Categories: Amino Acids, Peptides, and Proteins, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, antagonists & inhibitorsGlyceryl laurate
go.drugbank.com/drugs/DB16635InvestigationalCategories: Compounds used in a research, industrial, or household settingTanezumab
go.drugbank.com/drugs/DB12335InvestigationalTanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic.
Categories: Amino Acids, Peptides, and ProteinsPolyestradiol phosphate
go.drugbank.com/drugs/DB09369ApprovedPolymeric phosphoric acid ester of estradiol.
Categories: Hormones and Related Agents, Antineoplastic and Immunomodulating AgentsCoblopasvir
go.drugbank.com/drugs/DB15315InvestigationalCoblopasvir is under investigation in clinical trial NCT03416491 (Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis C).
INCB7839
go.drugbank.com/drugs/DB05033InvestigationalIt represents a potentially important new class of targeted breast cancer therapy. It has shown promising clinical activity in heavily pretreated, refractory breast cancer patients. … INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways.